Palisade Bio Inc
PALI
View Detailed Chart
1.720USD
-0.240-12.24%
Market hours （ET）Quotes delayed by 15 min
79.48Market Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-12.24%
5 Days
-8.99%
1 Month
-2.82%
6 Months
+86.61%
Year to Date
-26.81%
1 Year
+149.75%
View Detailed Chart
TradingKey Stock Score of Palisade Bio Inc
Currency: USD Updated: 2026-03-27Key Insights
Palisade Bio Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 130 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Palisade Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Palisade Bio Inc Highlights
StrengthsRisks
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -6.63, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 68.41M shares, increasing 49.82% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.12M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.49.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
11.375
Target Price
+480.36%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Palisade Bio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Palisade Bio Inc Info
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
Ticker SymbolPALI
CompanyPalisade Bio Inc
CEOFinley (J. D.)
Websitehttps://palisadebio.com/
Related Instruments
-0.60%
+1.00%
+1.20%
+3.16%
-1.13%
+0.71%
+0.39%
-0.80%
+0.23%
-0.06%
+1.81%
+0.51%
+0.87%
+1.99%
-3.06%
0.00%
+0.24%
-0.79%
-0.52%
+1.22%Popular Symbols
247.030
-1.770 (-0.71%)
166.770
-0.750 (-0.45%)
67240.430
+656.380 (+0.99%)
253.970
-19.380 (-7.09%)
2061.510
+61.510 (+3.08%)
359.997
-1.833 (-0.51%)
4532.520
+40.000 (+0.89%)
102.622
+2.013 (+2.00%)
1.146
-0.004 (-0.39%)
159.464
-0.788 (-0.49%)
